(34.204.187.106)
Users online: 2471    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 6
First page : ( 2992) Last page : ( 2996)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00529.6

An Overview of DRF in the treatment of Multiple Sclerosis

Varshney Prabhat*, Saini Prem**

School of Pharmacy, Lingaya's Vidyapeeth, Faridabad, Haryana-121002, India

*Corresponding Author E-mail: prabhatvarshney.pv@gmail.com

**prem_hsaini@yahoo.co.in

Online published on 4 July, 2020.

Abstract

Diroximel fumarate (DRF) is an oral disease-modifying agent indicated for the treatment of relapsing-remitting multiple sclerosis (RRMS), which is taken twice a day. In EVOLVE-MS-1, Phase 3, a two-year safety study evaluating DRF in patients with RRMS, it is shown that the occurrence of flushing and gastrointestinal treatment-emergent adverse events is comparatively low. This results in a low rate of discontinuation due to treatment-emergent adverse events as compared to dimethyl fumarate (DMF). Monomethyl fumarate (MMF) is a common active metabolite of DMF and DRF. This active metabolite is responsible for the mechanism of actions of the drugs since it crossed the blood-brain barrier. Methanol is the primary metabolite of DMF metabolism but a minor metabolite of DRF metabolism, which results in a lower risk of gastrointestinal symptoms. Both DMF and DRF show similar Tmax and Cmax, which indicate similarity in the efficacy of both the drugs. Therefore, DRF has a similar safety and efficacy profile but better tolerability of treatment-emergent adverse events when compared to DMF. This article provides an updated overview of the pharmacological, therapeutic efficacy, and tolerability of DRF.

Top

Keywords

Sclerosis, Diroximel Fumarate, Monomethyl Fumarate, Gasterointestinal, Relapsing-Remitting Multiple Sclerosis.

Top

 
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
429,683,552 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.